Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be associated with a reduced rate of adverse events, seen…
- Trial name
- NCT00323544
- Testing
- zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen
A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based…
- Trial name
- FATI-01 (NCT01714414)
- Testing
- FZD, 3TC, EFV
- Where
- 2 sites in Côte d’Ivoire, Tanzania
- Volunteers
- 120 people
- Sponsor
- Michael Hoelscher
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.
- Trial name
- ASTRAL-5 (NCT02480712)
- Testing
- SOF/VEL
- Where
- 15 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
HIV Infection
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men
The purpose of this study is to examine safety and tolerability of daily tenofovir use in HIV-uninfected men.
- Trial name
- NCT00131677
- Testing
- tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
This study will evaluate the signs and symptoms associated with Fuzeon injection (90mg sc) using the B2000 needle-free injection device, in HIV-1 positive patients experienced to Fuzeon treatment, but having difficulty tolerating…
- Trial name
- NCT00337701
- Testing
- enfuvirtide [Fuzeon]
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- Hoffmann-La Roche
HIV -1 Infection
Analyses of Newly Diagnosed HIV Infection in Hong Kong
The goal of the project is to determine the epidemiologic status and changing patterns of HIV infection in Hong Kong. The main question it aims to answer is: what is the molecular pattern and burden of HIV-1 infections over the…
- Trial name
- NCT07725042
- Where
- Hong Kong
- Volunteers
- 720 people
- Sponsor
- Chinese University of Hong Kong
HIV Infections
A Pilot Study of LTB4 in HIV-1 Infected Adults
This is a pilot study to assess the safety and antiretroviral activity of a naturally occuring substance known as Leukotriene B4(LTB4).
- Trial name
- NCT00251537
- Testing
- LTB4
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- LTB4 Sweden AB
HIV Infections
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks).
- Trial name
- DAYANA (NCT00573001)
- Testing
- Tenofovir/Emtricitabine (Truvada) and Nevirapine, Tenofovir/Emtricitabine/Efavirenz (Atripla), Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 120 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-1-infection
Reducing Antiretroviral Treatments
The purpose of this trial is to demonstrate at W48 the non-inferiority of a dual nucleoside analogues strategy with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC) preceded by a 16 week…
- Trial name
- ALTAR (NCT04051970)
- Testing
- Antiretroviral
- Where
- France
- Volunteers
- 360 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People
Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses of IFN necessary to keep HIV under control limit its use due to toxic side effects.
- Trial name
- NCT00078442
- Testing
- Pegylated interferon alfa-2a
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV-1-infection
Cytomegalovirus Infection in Patients With HIV-1 Infection
The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (< 50 copies/ml) for at least 2 years and to…
- Trial name
- ACTHIV (NCT04067869)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 392 people
- Sponsor
- University Hospital, Bordeaux
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day…
- Trial name
- NCT03739866
- Testing
- Lenacapavir, B/F/TAF, TAF
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
The primary objectives of this study are to evaluate the safety and tolerability of escalating, multiple doses of vesatolimod (formerly GS-9620) in HIV-1 infected virologically suppressed adults on antiretroviral therapy (ART)…
- Trial name
- NCT02858401
- Testing
- Vesatolimod, ARV regimen
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
HIV-1
TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
The purpose of this study is: to determine the safety, (local) tolerability and plasma exposure over time of single intramuscular (IM) doses of 600 and 1200 mg of a new formulation (F006) of TMC278LA, to determine the safety…
- Trial name
- NCT00741741
- Testing
- TMC278
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Papilloma Virus, Human
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists.
- Trial name
- HPV (NCT01206556)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an antiretroviral drug.
- Trial name
- NCT00050856
- Testing
- Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
- Trial name
- NCT00000809
- Testing
- Aluminum hydroxide, QS-21, MN rsgp120/HIV-1
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Heroin Dependence
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Though the HIV epidemic in India is predominantly among heterosexual populations, it is estimated that there are approximately 1.1 million injection drug users (IDUs) in India with HIV prevalence as high as 64% among IDUs in…
- Trial name
- DAART+ (NCT00709007)
- Testing
- Directly Administered Antiretroviral Therapy (DAART), SAT
- Where
- India
- Sponsor
- Johns Hopkins University
HIV Infections
Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults
The purpose of this study is to evaluate the safety and immunogenicity of the IHV01 protein vaccine primed and co-administered with HIV DNA CON-S env vaccine in healthy, HIV-1-uninfected adults.
- Trial name
- NCT03505060
- Testing
- DNA CON-S env, IHV01
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
For PRAM-1: To evaluate zidovudine (ZDV) + lamivudine (3TC) vs. stavudine (d4T) + ritonavir vs. ZDV + 3TC + ritonavir with respect to the change in plasma HIV-1 RNA copy number from baseline to 48 weeks [AS PER AMENDMENT 1/5/98…
- Trial name
- NCT00001083
- Testing
- Indinavir sulfate, Ritonavir, Nevirapine
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.